Discover our Portfolio
Altimmune is a clinical biotechnology company located in Maryland (USA); the company develops immunotherapies for several diseases, including acute respiratory infections and chronic viral infections, capitalizing on two innovative vaccine distribution platforms: RepirVec ™ and Densigen ™.
Altimmune’s positive progress was announced at the end Q1 2018:
- On the vaccine program NasoVax™ (licensed injectable seasonal influenza vaccine): proof of concept positive from phase 2a clinical trial
- Positive preclinical survival and immunogenicity data for the Phase 2 SparVax-L program (prevention of anthrax infection)
The positive results of the NasoVAX study enable to look forward to a new approach to fight influenza; NasoVAX could become effective and easy to administer flu vaccine which may offer broader and longer lasting protection than current vaccines.